全文获取类型
收费全文 | 66878篇 |
免费 | 5390篇 |
国内免费 | 4578篇 |
专业分类
耳鼻咽喉 | 397篇 |
儿科学 | 1737篇 |
妇产科学 | 844篇 |
基础医学 | 12430篇 |
口腔科学 | 1336篇 |
临床医学 | 5893篇 |
内科学 | 10374篇 |
皮肤病学 | 1004篇 |
神经病学 | 4438篇 |
特种医学 | 1343篇 |
外国民族医学 | 31篇 |
外科学 | 3547篇 |
综合类 | 13613篇 |
现状与发展 | 22篇 |
一般理论 | 1篇 |
预防医学 | 3552篇 |
眼科学 | 1164篇 |
药学 | 5391篇 |
4篇 | |
中国医学 | 1641篇 |
肿瘤学 | 8084篇 |
出版年
2024年 | 140篇 |
2023年 | 698篇 |
2022年 | 1496篇 |
2021年 | 2076篇 |
2020年 | 1793篇 |
2019年 | 1757篇 |
2018年 | 1657篇 |
2017年 | 1886篇 |
2016年 | 2116篇 |
2015年 | 2238篇 |
2014年 | 3479篇 |
2013年 | 4519篇 |
2012年 | 3717篇 |
2011年 | 4553篇 |
2010年 | 3747篇 |
2009年 | 3736篇 |
2008年 | 3976篇 |
2007年 | 4272篇 |
2006年 | 4037篇 |
2005年 | 3761篇 |
2004年 | 3398篇 |
2003年 | 2937篇 |
2002年 | 2552篇 |
2001年 | 2297篇 |
2000年 | 1941篇 |
1999年 | 1608篇 |
1998年 | 1411篇 |
1997年 | 1169篇 |
1996年 | 851篇 |
1995年 | 729篇 |
1994年 | 544篇 |
1993年 | 364篇 |
1992年 | 281篇 |
1991年 | 235篇 |
1990年 | 198篇 |
1989年 | 127篇 |
1988年 | 95篇 |
1987年 | 69篇 |
1986年 | 55篇 |
1985年 | 93篇 |
1984年 | 60篇 |
1983年 | 33篇 |
1982年 | 42篇 |
1981年 | 32篇 |
1980年 | 23篇 |
1979年 | 18篇 |
1978年 | 8篇 |
1977年 | 8篇 |
1976年 | 4篇 |
1975年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
瘢痕疙瘩是烧伤外科研究的重要课题,其形成机制尚未完全明确,本文就其在遗传机制、免疫作用、细胞增殖与胶原代谢、细胞因子等方面的研究进展进行综述。 相似文献
22.
Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis. 总被引:1,自引:1,他引:0
Rolf Dario Frank Vincent M Brandenburg Regina Lanzmich Jürgen Floege 《Nephrology, dialysis, transplantation》2004,19(6):1552-1558
BACKGROUND: Low molecular weight heparins (LMWH) like dalteparin are increasingly used for anticoagulation during haemodialysis (HD). The available laboratory tests for monitoring LMWH anticoagulation are time-consuming and expensive, and the suitability of the conventional activated clotting time (ACT) is controversial. A simple and cheap bedside test would be useful. METHODS: We studied the factor Xa-activated whole blood clotting time (Xa-ACT) in vitro and in vivo in nine patients undergoing chronic HD with i.v. dalteparin bolus anticoagulation and compared it with the conventional ACT. Plasma anti-factor Xa (antiXa) activity was determined with a chromogenic assay. Thrombin-antithrombin complexes were measured to detect coagulation activation. RESULTS: Xa-ACT and ACT were prolonged with rising dalteparin concentration. In vitro, both clotting times were strongly correlated with the antiXa levels (r = 0.94 and 0.89, respectively). Nevertheless, compared with the ACT, the Xa-ACT was considerably more sensitive to the LMWH in vitro (healthy blood: Xa-ACT 90 s/U vs ACT 26 s/U; uraemic blood: Xa-ACT 96 s/U vs ACT 31 s/U) as well as in vivo (Xa-ACT 81 s/U vs ACT 22 s/U) and reflected different intensities of anticoagulation. An initial dalteparin bolus of 80+/-11 U/kg body weight was able to prevent coagulation activation for up to 4 h of HD. CONCLUSION: For monitoring LMWH anticoagulation the Xa-ACT was superior to the conventional ACT in vitro as well as in vivo during HD. The Xa-ACT can be useful as a LMWH bedside test. The ACT was not sensitive enough to serve as a LMWH monitoring tool. 相似文献
23.
Hideaki Iwaki Kazuyoshi Johnin Susumu Kageyama Chul Jang Kim Takahiro Isono Tatsuhiro Yoshiki 《International journal of urology》2007,14(10):918-923
OBJECTIVES: Vesicoureteral reflux (VUR) is the most common congenital urinary tract anomaly. This disease can pose a major threat to the kidneys as twenty percent of patients with endstage renal disease are reported to have VUR. Although genetic studies for uroplakin III (UPIII) have been reported recently, no study has focused on UPIII gene expression in VUR patients. We describe here the up-regulation of UPIII mRNA in exfoliated urinary cells from primary VUR patients. METHODS: A real-time RT-PCR for UPIII mRNA was performed on exfoliated urothelial cells from 18 primary VUR and 38 control samples. UPIII mRNA copies were calculated for each sample. The statistical differences were assessed by the Mann-Whitney U test. Receiver operator characteristic curves were constructed for analysis of the diagnostic values. RESULTS: UPIII mRNA was found to be up-regulated to a greater extent in VUR than in control exfoliated urinary cells (mean +/- SE: 497.0 +/- 178.5 copies vs. 69.0 +/- 10.0 copies, respectively, P < 0.001). In evaluating the measurement of urinary UPIII mRNA as a screening test for VUR, the sensitivity was 77.8% and the specificity was 76.3% by the best diagnostic cutoff point. CONCLUSIONS: This is the first report demonstrating up-regulation of UPIII in mRNA levels in VUR patients. We submit that the quantitative measurement of urinary UPIII mRNA has a potential of developing into the first non-invasive screening test for VUR. 相似文献
24.
Tae-Jin Song M.D. Ph.D. David P. Eisenberg M.D. Prasad S. Adusumilli M.D. Michael Hezel B.S. Yuman Fong M.D. 《Journal of gastrointestinal surgery》2006,10(4):532-542
The rising incidence of hepatocellular carcinoma (HCC) in western countries, along with the poor prognosis offered by present-day
treatment modalities, makes novel therapies for this disease necessary. Oncolytic herpes simplex viruses (HSV) are replication-competent
viruses that are highly effective in the treatment of a wide variety of experimental models of human malignancies. This study
seeks to investigate the effectiveness of oncolytic herpes viruses in the treatment of primary HCC cell lines. Sixteen commercially
available human HCC cell lines were studied. G207 is an attenuated, replication-competent, oncolytic HSV engineered to selectively
replicate within cancer cells. Cell lines were tested for viral sensitivity to G207 and their ability to support viral replication
using standard cytotoxicity and viral replication assays. Eleven of 16 cell lines were moderately to highly sensitive to G207
viral oncolysis. HCC cell lines additionally demonstrated the ability to support viral replication in vitro with as high as
800-fold amplification of the administered viral dose observed. G207 is cytotoxic to, and efficiently replicates within, HCC
cell lines in vitro. From these data, we suggest that oncolytic HSV therapy may have a role in the treatment of HCC, and in
vivo studies are warranted.
Presented in part at the 2005 American Hepato-Pancreato-Biliary Association Congress, Hollywood, Florida, April 14–17, 2005.
Supported by grants R01CA75461 and R01CA72632 from the National Institutes of Health, and by grant MBC-99366 from the American
Cancer Society (Yuman Fong). 相似文献
25.
目的探讨自发性高血压大鼠颈动脉中抑癌基因P53和原癌基因c-jun、c-fos、c-myc mRNA的表达.方法用逆转录聚合酶链式反应检测两种基因的表达水平.正常雄性大鼠作为对照组.结果 SHR颈动脉中,抑癌基因P53和原癌基因c-jun、c-fos、c-myc均有高表达,较WKY差异有显著性(P<0.05).结论自发性高血压大鼠颈动脉组织中抑癌基因P53和原癌基因c-jun、c-fos、c-myc均有高表达,癌基因的活化可能与自发性高血压大鼠颈动脉血管重构有关. 相似文献
26.
27.
Gene delivery systems are designed to control the location of administered therapeutic genes within a patient's body. Successful in vivo gene transfer may require (i) the condensation of plasmid and its protection from nuclease degradation, (ii) cellular interaction and internalization of condensed plasmid, (iii) escape of plasmid from endosomes (if endocytosis is involved), and (iv) plasmid entry into cell nuclei. Expression plasmids encoding a therapeutic protein can be, for instance, complexed with cationic liposomes or micelles in order to achieve effective in vivo gene transfer. A thorough knowledge of pharmaceutics and drug delivery, bio-engineering, as well as cell and molecular biology is required to design optimal systems for gene therapy. This mini-review provides a critical discussion on cationic lipid-based gene delivery systems and their possible uses as pharmaceuticals. 相似文献
28.
经逆转录病毒载体将人GM-CSF基因导入人膀胱癌细胞株BIU-87细胞中,建立了转基因细胞株BIU/GM。经流式细胞仪行细胞DNA周期分析表明GM-CSF基因的导人及表达对BIU-87细胞的增长无影响。免疫荧光测定发现转GM-CSF基因及表达不能促进BIU-87细胞表面HLA-ABC、DR、DQ抗原的表达。转基因瘤细胞株经6000rad X射线照射灭活后,丧失增殖能力,逐步死亡,但能维持一定水平的GM-CSF分泌活性达两周以上。从而为制备灭活的转基因瘤苗提供了初步经验。 相似文献
29.
Tsutomu Ogata Peter Goodfellow Christine Petit Pierre Maroteaux Nobutake Matsuo 《American journal of medical genetics. Part A》1993,45(1):101-104
This is a follow-up report on a male patient with a 46, Y, r(X) karyotype. Although he had no clinico-radiological features of X-linked recessive chondrodysplasia punctata (CDPX1), molecular studies revealed an Xp terminal deletion involving the putative region for the CDPX1 locus (PABX-DXS31). We suspect that the absence of CDPX1 may be attributable to the nature of the disease and the extreme short stature of the patient (mean – 5.6 S.D.). © 1993 Wiley-Liss, Inc. 相似文献
30.
目的:探讨人卵巢癌标本中,肿瘤转移抑制基因nm23-H1编码蛋白NDPK-A表达的临床意义及其与预后的关系。方法:应用免疫组织化学抗生蛋白链菌素-过氧化酶结合(S-P)法,检测58例人卵巢癌标本中nm23-H1蛋白水平。结果:nm23-H1蛋白的表达与患者手术时是否有淋巴结及大网膜转移相关(P〈0.05),但原发灶与转移灶间的阳性表达率相差不显著;与患者术后生存时间密切相关(P〈0.01),术后生 相似文献